Inhibikase Therapeutics (IKT) Revenue (2020 - 2023)

Inhibikase Therapeutics (IKT) has 4 years of Revenue data on file, last reported at $1.0 in Q4 2023.

• On a quarterly basis, Revenue fell 100.0% year-over-year to $1.0 in Q4 2023; TTM through Sep 2024 was $1.0, a 100.0% decrease from a year earlier, with the FY2023 full-year figure at $260501.0, up 111.03% from the prior year.
• Revenue for Q4 2023 stood at $1.0, down from $79569.0 in the prior quarter.
• Over the last five years, Revenue for IKT reached as high as $1.4 million in Q1 2021 and fell as low as $1.0 in Q4 2023.
• Historically, Revenue has averaged $261438.4 across 4 years, with a median of $72045.0 in 2023.
• Across the five-year window, Revenue jumped 3169.86% in 2022 and plunged 100.0% in 2023, its largest moves.
• Year by year, Revenue stood at $170416.0 in 2020, then tumbled by 98.86% to $1944.0 in 2021, then soared by 3169.86% to $63566.0 in 2022, then plunged by 100.0% to $1.0 in 2023.
• Per Business Quant data, the three most recent Revenue figures were $1.0 in Q4 2023, $79569.0 in Q3 2023, and $116410.0 in Q2 2023.